These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 3279301)
1. Neurochemical pathology and the etiology of Parkinson's disease: basic facts and hypothetical possibilities. Hornykiewicz O Mt Sinai J Med; 1988 Jan; 55(1):11-20. PubMed ID: 3279301 [No Abstract] [Full Text] [Related]
2. Parkinson's disease: etiological considerations. Barbeau A Res Publ Assoc Res Nerv Ment Dis; 1976; 55():281-92. PubMed ID: 1005903 [No Abstract] [Full Text] [Related]
3. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Lotharius J; Brundin P Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550 [No Abstract] [Full Text] [Related]
4. Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease. Diamond BI; Pasinetti G; Hitri A; Borison RL Adv Neurol; 1984; 40():483-8. PubMed ID: 6695625 [No Abstract] [Full Text] [Related]
5. [New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP]. Jonsson G; Sundström E Lakartidningen; 1986 Jan; 83(4):215-8. PubMed ID: 3485230 [No Abstract] [Full Text] [Related]
6. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068 [TBL] [Abstract][Full Text] [Related]
7. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease. Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154 [TBL] [Abstract][Full Text] [Related]
8. Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease. Benedetto A; Au C; Aschner M Chem Rev; 2009 Oct; 109(10):4862-84. PubMed ID: 19534496 [No Abstract] [Full Text] [Related]
10. What has been learnt from study of dopamine receptors in Parkinson's disease? Hurley MJ; Jenner P Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973 [TBL] [Abstract][Full Text] [Related]
11. Endogenous regeneration in Parkinson's disease: do we need orthotopic dopaminergic neurogenesis? Hermann A; Storch A Stem Cells; 2008 Nov; 26(11):2749-52. PubMed ID: 18719222 [No Abstract] [Full Text] [Related]
12. [Free radicals and ailing proteins--the culprits behind Parkinson disease?]. Smith R; Lotharius J; Brundin P Lakartidningen; 2003 Apr; 100(15):1324-6, 1329-30. PubMed ID: 12739402 [TBL] [Abstract][Full Text] [Related]
13. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations]. Morselli PL; Rizzo M; Tognoni G Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589 [No Abstract] [Full Text] [Related]
14. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Chu Y; Kordower JH Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279 [TBL] [Abstract][Full Text] [Related]